Secukinumab: A Review in Ankylosing Spondylitis
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01075-3
Abstract: Secukinumab (Cosentyx®), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the… read more here.
Keywords: ankylosing spondylitis; treatment; review ankylosing; secukinumab ... See more keywords